Developer docs
API playgroundTry for free, no card

Search company profiles

Sysmex Corporation

Full company profile

uuid000epd4

Namestring
Sysmex Corporation
Legal namestring
Sysmex America, Inc.
Websiteurl
sysmex.com
Company typeenum
Public
Founded yearint
1968
Descriptiontext

Sysmex Corporation is a Japanese in vitro diagnostics company founded in 1968 and headquartered in Kobe, Japan, publicly listed in Tokyo and on OTCMKTS (SSMXY), with global operations including an Americas regional affiliate (Sysmex America, Inc.) in Lincolnshire, Illinois, and a Canadian subsidiary. The company specializes in clinical laboratory diagnostics spanning five solution areas: Hematology (XN-Series and the new XR-Series automated analyzers), Hemostasis (CN-Series and CS-Series coagulation analyzers), Urinalysis (UN-Series integrating UF-5000 particle counting with Siemens CLINITEK Novus chemistry and UD-10 digital imaging), Flow Cytometry, and Informatics Solutions (Caresphere Workflow Solution, BeyondCare Quality Monitor, and the Sysmex Network Communications System). The core technical platform is fluorescent flow cytometry using semiconductor laser and hydrodynamic focusing, complemented by AI-based digital cell morphology on the DI-60 system via artificial neural network pre-classification, and a proprietary informatics stack that integrates analyzers with peer QC and workflow automation.

Sysmex's business model combines hardware sales of analyzers with high-margin recurring revenue from proprietary reagents and consumables, plus multi-year service and support contracts delivered through programs like BeyondCare and SNCS remote monitoring. The company sells primarily through direct enterprise field sales to hospitals, reference laboratories, and clinical labs across the Americas, complemented by regional distributors in Latin America, Central America, Mexico, and the Caribbean, with self-described reach across 20+ countries. Pricing is quote-based on multi-year contracts structured around lab size and testing volume; no public list pricing is disclosed. The installed base comprises 12,000+ clinical laboratories worldwide performing 400+ million CBCs annually, producing deeply embedded switching costs through reagent attachment, IT integrations (Bio-Rad Unity Next, CellaVision software stack), and validated clinical workflows.

Recent strategic activity shows Sysmex leveraging this installed base and regulated distribution muscle to extend into adjacent verticals: regenerative medicine via the 2023 acquisition of iPS cell company Megakaryon; Alzheimer's/dementia immunoassays via the 2026 Fujirebio sales collaboration; AI-based bone marrow analysis via the 2026 CellaVision EMEA distribution partnership; and sepsis/NETs diagnostics via the 2026 VolitionRx collaboration. Product refreshes include the XR-Series hematology launch (2026-05) and the announced CN-9000 hemostasis system (2026-07), alongside a 2023 European first for point-of-care antimicrobial susceptibility testing. The portfolio continues to be anchored by core XN-Series hematology analyzers, hemostasis platforms with Preanalytical Sample Integrity (PSI) checks, and integrated urinalysis solutions, with the 26-consecutive-year #1 IMV ServiceTrak system reliability ranking reinforcing the company's brand moat in regulated clinical environments.

Short descriptiontext

Sysmex Corporation is a Japanese in vitro diagnostics company that develops and sells automated hematology, hemostasis, urinalysis, and flow cytometry analyzers, along with reagents and informatics, serving 12,000+ clinical laboratories worldwide and performing over 400 million CBCs annually.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLincolnshire, United States
HQ citystring
Lincolnshire
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hematology analyzers, clinical diagnostics, coagulation analyzers, flow cytometry reagents, laboratory informatics
Industry3 codes
PRIMARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
Product category
Clinical Diagnostics Instruments
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model6 records
1Hematology Instruments and Reagents
TypeHardware Sales
Description

Sale and servicing of automated hematology analyzers (XN-Series, XR-Series) along with配套 reagents and consumables for complete blood count testing

defenseworld.net
2Urinalysis Systems
TypeHardware Sales
Description

Integrated urinalysis solutions combining particle counting, chemistry analysis, and digital imaging with配套 reagents

defenseworld.net
3Hemostasis/Coagulation Products
TypeHardware Sales
Description

Blood coagulation analyzers (CN-6000, CS-5100, CS-2500, CA-600) and reagents for hemostasis testing including clotting, chromogenic, and immunoturbidimetric assays

defenseworld.net
4Flow Cytometry Instruments and Reagents
TypeHardware Sales
Description

Clinical flow cytometry systems and reagents for immunophenotyping and cell analysis applications

defenseworld.net
5Service and Support Contracts
TypeSubscription Recurring
Description

Technical support, maintenance, calibration, and remote monitoring services through Sysmex Network Communications System (SNCS) and BeyondCare programs

sysmex.com
6Digital PCR and Molecular Diagnostics
TypeHardware Sales
Description

Advanced molecular diagnostic technologies including digital PCR capabilities and integrated diagnostic solutions for precision medicine applications

openpr.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Enterprise laboratory instrumentation and reagents
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing; no public list pricing available. Sales conducted through direct enterprise field sales with customized quotations based on laboratory requirements, testing volumes, and service package selections.

sysmex.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1BeyondCare
Description

Service and support program offering evidence-based maintenance, quality monitoring, and remote technical assistance for Sysmex analyzers.

sysmex.com
+2 more records
Core offering1 text field

Sysmex Corporation manufactures and globally distributes in vitro diagnostic analyzers, proprietary reagents, and laboratory informatics software for clinical laboratories. Its core product lines span hematology, hemostasis/coagulation, urinalysis, flow cytometry, and immunochemistry analyzers, paired with corresponding reagents and consumables used by hospital labs, reference labs, and blood centers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sysmex Corporation offers a comprehensive diagnostic solutions portfolio organized into five core areas: Hematology, Hemostasis, Urinalysis, Flow Cytometry, and Informatics Solutions. The hematology portfolio includes the XN-Series automated analyzers (XN-1000, XN-2000, XN-3100, XN-9100) using fluorescent flow cytometry technology, complemented by the new XR-Series generation launched in 2026. Supporting products include SP-50 slidemaker/stainer, DI-60 digital cell morphology system with AI-powered pre-classification, BT-50 automated QC terminal, TS-01 tube sorter, and TA-01 tube archiver. The hemostasis line features CN-6000 and CN-3000 high-throughput coagulation analyzers, CS-5100 and CS-2500 systems, and CA-600 Series for lower-volume labs, all incorporating Preanalytical Sample Integrity (PSI) technology. Urinalysis solutions comprise the UN-Series (UN-2000, UN-3000, UN-9000) integrating UF-5000 particle counting, Siemens CLINITEK Novus chemistry, and UD-10 digital imaging, managed through Urinalysis Data Manager (UDM). Informatics offerings include BeyondCare Quality Monitor (BCQM), Caresphere Workflow Solution (WS), and Sysmex Network Communications System (SNCS) for remote monitoring. The portfolio operates on a platform-plus-modules architecture with scalable automation options designed for laboratories of all sizes.

Product and service1 record
1XN-Series Hematology Analyzers
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Collaboration to optimize VolitionRx's Nu.Q NETs H3.1 assay on Sysmex's in vitro diagnostics platform for detecting Neutrophil Extracellular Traps (NETs) associated with sepsis and other acute/chronic conditions. Companies have completed assay transfer and entered optimization phase. VolitionRx estimates $3.8 billion total addressable market for the Nu.Q NETs assay. Financial terms not disclosed.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-11
Description

Sysmex Corporation serves as exclusive distribution partner for CellaVision's AI-powered Bone Marrow Aspirate Application in EMEA region. Product runs on CellaVision DC-1 analyzer, automatically locates analysis areas, captures high-resolution images, and pre-classifies nucleated cells into 17 cell types. CE marked as Class C device under EU IVDR.

3Fujirebio Holdings
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-05
Description

Sales collaboration agreement for dementia testing where Sysmex exclusively sells Fujirebio's fully automated Lumipulse immunoassay systems and dementia-related reagents in regions mutually agreed upon. Collaboration begins in Brazil and progressively expands into Central and South America, Middle East, Asia, and other regions. Addresses growing demand for dementia testing accompanying adoption of new therapeutic drugs for Alzheimer's disease.

pharmiweb.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-12-21
Description

Sysmex acquired iPS (induced pluripotent stem cell) company Megakaryon to accelerate development of regenerative medicine. Acquisition strengthens Sysmex's position in cell therapy and regenerative medicine applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1Beckman Coulter
TypeDirect peer
Description

Now part of Danaher's Diagnostics platform, Beckman Coulter is the closest direct competitor to Sysmex in hematology analyzers (DxH series) and offers overlapping urinalysis and hemostasis workflows for clinical laboratories.

TypeBroad incumbent
Description

Diversified diagnostics incumbent offering Atellica/ADVIA Centaur hematology, hemostasis (BCS/XP), and integrated lab automation; Sysmex integrates with Siemens CLINITEK Novus urine chemistry within its UN-Series, making Siemens both a partner and competitor.

TypeEmerging player
Description

Smaller IVD player active in hematology (QuikRead, Hemo Control), point-of-care, and clinical chemistry; overlaps with Sysmex's lower-volume and decentralized testing footprint.

4Bou Diagnostics (Boulex)
TypeDirect peer
Description

Specialist hematology analyzer vendor (Medonic, Swelab) for low- and mid-volume labs; competes with Sysmex's XN-L and 3-part analyzer family in smaller hospital and clinic settings.

TypeDirect peer
Description

Provider of hematology controls (Liquichek) and Unity QC peer-comparison software; integrates with Sysmex XN-Series for QC management, making it both a partner and a complementary competitor for lab quality programs.

TypeBroad incumbent
Description

Largest diagnostics incumbent globally with cobas hematology, coagulation, and integrated lab automation; competes for the same multi-year enterprise contracts and reference lab business as Sysmex.

TypeDirect peer
Description

Chinese IVD player offering BC-7500/BC-6800Plus hematology analyzers and broader IVD menu; targets similar mid-to-high volume clinical lab segment and is an emerging direct global competitor to Sysmex, especially in emerging markets.

8Abbott Diagnostics
TypeBroad incumbent
Description

Major IVD incumbent with CELL-DYN/Alinity hq hematology, broader immunoassay, and a leading point-of-care franchise (i-STAT); competes with Sysmex in hospital and reference lab channels across the full diagnostic menu.

TypeDirect peer
Description

Specialist hematology and hemostasis analyzer manufacturer (Pentra, Yumizen, ABX product lines) competing directly with Sysmex in small-to-mid volume hospital and physician-office lab segments.

TypeEmerging player
Description

Digital cell morphology specialist whose DC-1 analyzer and AI applications are distributed exclusively by Sysmex in EMEA; a channel partner that is also an emerging competitive threat in digital morphology as labs consider standalone digital solutions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sysmex Corporation

Clinical Diagnostics Instrumentssysmex.com

Sysmex Corporation is a Japanese in vitro diagnostics company that develops and sells automated hematology, hemostasis, urinalysis, and flow cytometry analyzers, along with reagents and informatics, serving 12,000+ clinical laboratories worldwide and performing over 400 million CBCs annually.

What Sysmex Corporation does

Sysmex Corporation is a Japanese in vitro diagnostics company founded in 1968 and headquartered in Kobe, Japan, publicly listed in Tokyo and on OTCMKTS (SSMXY), with global operations including an Americas regional affiliate (Sysmex America, Inc.) in Lincolnshire, Illinois, and a Canadian subsidiary. The company specializes in clinical laboratory diagnostics spanning five solution areas: Hematology (XN-Series and the new XR-Series automated analyzers), Hemostasis (CN-Series and CS-Series coagulation analyzers), Urinalysis (UN-Series integrating UF-5000 particle counting with Siemens CLINITEK Novus chemistry and UD-10 digital imaging), Flow Cytometry, and Informatics Solutions (Caresphere Workflow Solution, BeyondCare Quality Monitor, and the Sysmex Network Communications System). The core technical platform is fluorescent flow cytometry using semiconductor laser and hydrodynamic focusing, complemented by AI-based digital cell morphology on the DI-60 system via artificial neural network pre-classification, and a proprietary informatics stack that integrates analyzers with peer QC and workflow automation.

Sysmex's business model combines hardware sales of analyzers with high-margin recurring revenue from proprietary reagents and consumables, plus multi-year service and support contracts delivered through programs like BeyondCare and SNCS remote monitoring. The company sells primarily through direct enterprise field sales to hospitals, reference laboratories, and clinical labs across the Americas, complemented by regional distributors in Latin America, Central America, Mexico, and the Caribbean, with self-described reach across 20+ countries. Pricing is quote-based on multi-year contracts structured around lab size and testing volume; no public list pricing is disclosed. The installed base comprises 12,000+ clinical laboratories worldwide performing 400+ million CBCs annually, producing deeply embedded switching costs through reagent attachment, IT integrations (Bio-Rad Unity Next, CellaVision software stack), and validated clinical workflows.

Recent strategic activity shows Sysmex leveraging this installed base and regulated distribution muscle to extend into adjacent verticals: regenerative medicine via the 2023 acquisition of iPS cell company Megakaryon; Alzheimer's/dementia immunoassays via the 2026 Fujirebio sales collaboration; AI-based bone marrow analysis via the 2026 CellaVision EMEA distribution partnership; and sepsis/NETs diagnostics via the 2026 VolitionRx collaboration. Product refreshes include the XR-Series hematology launch (2026-05) and the announced CN-9000 hemostasis system (2026-07), alongside a 2023 European first for point-of-care antimicrobial susceptibility testing. The portfolio continues to be anchored by core XN-Series hematology analyzers, hemostasis platforms with Preanalytical Sample Integrity (PSI) checks, and integrated urinalysis solutions, with the 26-consecutive-year #1 IMV ServiceTrak system reliability ranking reinforcing the company's brand moat in regulated clinical environments.

Sysmex Corporation firmographics

Firmographics
Name
Sysmex Corporation
Legal name
Sysmex America, Inc.
Website
https://sysmex.com
Company type
Public
Founded year
1968
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Sysmex Corporation is a Japanese in vitro diagnostics company that develops and sells automated hematology, hemostasis, urinalysis, and flow cytometry analyzers, along with reagents and informatics, serving 12,000+ clinical laboratories worldwide and performing over 400 million CBCs annually.
Ownership category
akta.pro rank

Sysmex Corporation industry classification

Industry
Product category
Clinical Diagnostics Instruments
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)

Keywords

  • Hematology analyzers
  • Clinical diagnostics
  • Coagulation analyzers
  • Flow cytometry reagents
  • Laboratory informatics

Where Sysmex Corporation is headquartered

Location

Headquarters

HQ city
Lincolnshire
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Sysmex Corporation business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Hematology Instruments and Reagents: Sale and servicing of automated hematology analyzers (XN-Series, XR-Series) along with配套 reagents and consumables for complete blood count testing
  2. Urinalysis Systems: Integrated urinalysis solutions combining particle counting, chemistry analysis, and digital imaging with配套 reagents
  3. Hemostasis/Coagulation Products: Blood coagulation analyzers (CN-6000, CS-5100, CS-2500, CA-600) and reagents for hemostasis testing including clotting, chromogenic, and immunoturbidimetric assays
  4. Flow Cytometry Instruments and Reagents: Clinical flow cytometry systems and reagents for immunophenotyping and cell analysis applications
  5. Service and Support Contracts: Technical support, maintenance, calibration, and remote monitoring services through Sysmex Network Communications System (SNCS) and BeyondCare programs
  6. Digital PCR and Molecular Diagnostics: Advanced molecular diagnostic technologies including digital PCR capabilities and integrated diagnostic solutions for precision medicine applications

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise laboratory instrumentation and reagents

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Sysmex Corporation product offering

Product offering

Core offering

Sysmex Corporation manufactures and globally distributes in vitro diagnostic analyzers, proprietary reagents, and laboratory informatics software for clinical laboratories. Its core product lines span hematology, hemostasis/coagulation, urinalysis, flow cytometry, and immunochemistry analyzers, paired with corresponding reagents and consumables used by hospital labs, reference labs, and blood centers.

Product overview

Sysmex Corporation offers a comprehensive diagnostic solutions portfolio organized into five core areas: Hematology, Hemostasis, Urinalysis, Flow Cytometry, and Informatics Solutions. The hematology portfolio includes the XN-Series automated analyzers (XN-1000, XN-2000, XN-3100, XN-9100) using fluorescent flow cytometry technology, complemented by the new XR-Series generation launched in 2026. Supporting products include SP-50 slidemaker/stainer, DI-60 digital cell morphology system with AI-powered pre-classification, BT-50 automated QC terminal, TS-01 tube sorter, and TA-01 tube archiver. The hemostasis line features CN-6000 and CN-3000 high-throughput coagulation analyzers, CS-5100 and CS-2500 systems, and CA-600 Series for lower-volume labs, all incorporating Preanalytical Sample Integrity (PSI) technology. Urinalysis solutions comprise the UN-Series (UN-2000, UN-3000, UN-9000) integrating UF-5000 particle counting, Siemens CLINITEK Novus chemistry, and UD-10 digital imaging, managed through Urinalysis Data Manager (UDM). Informatics offerings include BeyondCare Quality Monitor (BCQM), Caresphere Workflow Solution (WS), and Sysmex Network Communications System (SNCS) for remote monitoring. The portfolio operates on a platform-plus-modules architecture with scalable automation options designed for laboratories of all sizes.

Differentiator

Problem solved

Functional benefit

Brands

  • BeyondCare: Service and support program offering evidence-based maintenance, quality monitoring, and remote technical assistance for Sysmex analyzers.
  • Caresphere
  • Sysmex University

Products and services

  • XN-Series Hematology Analyzers

Companies that use Sysmex Corporation

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Sysmex Corporation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability2 records

Feature7 records

Sysmex Corporation partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and strategic.

  • VolitionRx LimitedcoreStrategic or Co-development Partner · 17 June 2026Collaboration to optimize VolitionRx's Nu.Q NETs H3.1 assay on Sysmex's in vitro diagnostics platform for detecting Neutrophil Extracellular Traps (NETs) associated with sepsis and other acute/chronic conditions. Companies have completed assay transfer and entered optimization phase. VolitionRx estimates $3.8 billion total addressable market for the Nu.Q NETs assay. Financial terms not disclosed.
  • CellaVision ABcoreChannel Partner/ Reseller/ Distributor · 11 March 2026Sysmex Corporation serves as exclusive distribution partner for CellaVision's AI-powered Bone Marrow Aspirate Application in EMEA region. Product runs on CellaVision DC-1 analyzer, automatically locates analysis areas, captures high-resolution images, and pre-classifies nucleated cells into 17 cell types. CE marked as Class C device under EU IVDR.
  • Fujirebio HoldingscoreChannel Partner/ Reseller/ Distributor · 5 February 2026Sales collaboration agreement for dementia testing where Sysmex exclusively sells Fujirebio's fully automated Lumipulse immunoassay systems and dementia-related reagents in regions mutually agreed upon. Collaboration begins in Brazil and progressively expands into Central and South America, Middle East, Asia, and other regions. Addresses growing demand for dementia testing accompanying adoption of new therapeutic drugs for Alzheimer's disease.
  • Megakaryon CorporationstrategicStrategic or Co-development Partner · 21 December 2023Sysmex acquired iPS (induced pluripotent stem cell) company Megakaryon to accelerate development of regenerative medicine. Acquisition strengthens Sysmex's position in cell therapy and regenerative medicine applications.

Scale indicators6 records

Recent moves6 records

Expansion highlights8 records

Sysmex Corporation competitors and assessment

Company assessment

Direct peers

  • Beckman Coulter: Now part of Danaher's Diagnostics platform, Beckman Coulter is the closest direct competitor to Sysmex in hematology analyzers (DxH series) and offers overlapping urinalysis and hemostasis workflows for clinical laboratories.
  • Bou Diagnostics (Boulex): Specialist hematology analyzer vendor (Medonic, Swelab) for low- and mid-volume labs; competes with Sysmex's XN-L and 3-part analyzer family in smaller hospital and clinic settings.
  • Bio-Rad Laboratories: Provider of hematology controls (Liquichek) and Unity QC peer-comparison software; integrates with Sysmex XN-Series for QC management, making it both a partner and a complementary competitor for lab quality programs.
  • Mindray: Chinese IVD player offering BC-7500/BC-6800Plus hematology analyzers and broader IVD menu; targets similar mid-to-high volume clinical lab segment and is an emerging direct global competitor to Sysmex, especially in emerging markets.
  • Horiba Medical: Specialist hematology and hemostasis analyzer manufacturer (Pentra, Yumizen, ABX product lines) competing directly with Sysmex in small-to-mid volume hospital and physician-office lab segments.

Broad incumbents

  • Siemens Healthineers: Diversified diagnostics incumbent offering Atellica/ADVIA Centaur hematology, hemostasis (BCS/XP), and integrated lab automation; Sysmex integrates with Siemens CLINITEK Novus urine chemistry within its UN-Series, making Siemens both a partner and competitor.
  • Roche Diagnostics: Largest diagnostics incumbent globally with cobas hematology, coagulation, and integrated lab automation; competes for the same multi-year enterprise contracts and reference lab business as Sysmex.
  • Abbott Diagnostics: Major IVD incumbent with CELL-DYN/Alinity hq hematology, broader immunoassay, and a leading point-of-care franchise (i-STAT); competes with Sysmex in hospital and reference lab channels across the full diagnostic menu.

Emerging players

  • EKF Diagnostics: Smaller IVD player active in hematology (QuikRead, Hemo Control), point-of-care, and clinical chemistry; overlaps with Sysmex's lower-volume and decentralized testing footprint.
  • CellaVision: Digital cell morphology specialist whose DC-1 analyzer and AI applications are distributed exclusively by Sysmex in EMEA; a channel partner that is also an emerging competitive threat in digital morphology as labs consider standalone digital solutions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Sysmex Corporation social profiles

Digital presence

Sysmex Corporation compliance and trust

Trust signal

Compliance2 records

Sysmex Corporation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sysmex Corporation leadership team

Management profile

Number of profiles

Profiles2 records

Sysmex Corporation subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Sysmex Corporation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sysmex Corporation M&A and investment

M&A and investment

M&A2 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sysmex Corporation

What does Sysmex Corporation do?

Sysmex Corporation manufactures and globally distributes in vitro diagnostic analyzers, proprietary reagents, and laboratory informatics software for clinical laboratories. Its core product lines span hematology, hemostasis/coagulation, urinalysis, flow cytometry, and immunochemistry analyzers, paired with corresponding reagents and consumables used by hospital labs, reference labs, and blood centers.

Is Sysmex Corporation a public or private company?

Sysmex Corporation is a public company. It is classified as public and is currently operating.

When was Sysmex Corporation founded?

Sysmex Corporation was founded in 1968. It employs 1,001 to 5,000 people.

Where is Sysmex Corporation based?

Sysmex Corporation is headquartered in Lincolnshire, United States, in the North America region.

How does Sysmex Corporation make money?

Six revenue lines are on record. Hematology Instruments and Reagents are the primary driver. The others are urinalysis Systems, hemostasis/Coagulation Products, flow Cytometry Instruments and Reagents, service and Support Contracts and digital PCR and Molecular Diagnostics.

Who are Sysmex Corporation's main competitors?

Direct peers on record are Beckman Coulter, Bou Diagnostics (Boulex), Bio-Rad Laboratories, Mindray and Horiba Medical. Broad incumbents are Siemens Healthineers, Roche Diagnostics and Abbott Diagnostics. Emerging players are EKF Diagnostics and CellaVision.

Does Sysmex Corporation have an API?

No public API is recorded for Sysmex Corporation.

What industry is Sysmex Corporation in?

Sysmex Corporation's product category is Clinical Diagnostics Instruments. Its primary akta.pro industry code is HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls), with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StHere's What Analysts Are Forecasting For Sysmex Corporation (TSE:6869) After Its Half-Year ResultsSysmex Corporation reported half-year statutory earnings of JP¥15.30 per share, in line with forecasts, and revenue of JP¥273b, 2.8% above expectations. Analysts now forecast 2027 revenue of JP¥553.0b and EPS of JP¥68.21, up 19% from prior estimates, though the consensus price target remains unchanged at JP¥2,150.Investing.comEarnings call transcript: Sysmex beats Q2 2026 estimates, shares slipSysmex reported Q2 2026 EPS of $15.30 and revenue of $142.15 billion, both beating estimates. China sales fell 22.4% in local currency, while the Americas drove growth. The company kept its full-year forecast unchanged.Simply Wall StRaised Earnings Guidance Means For Shareholders In Sysmex (TSE:6869)Sysmex raised its earnings guidance for the six months to September 30, 2026, citing stronger Americas results despite a JPY 5,769 million impairment at Sysmex BioMajesty. It formed Saibogen with Hologen to apply generative AI to hematology data, aiming for software-based blood intelligence products. The guidance and AI push reshape the investment narrative, with execution risk on higher structural costs.MarketWatchSysmex Corp 1H Net Y17.93B Vs Net Y19.02BSysmex Corp reported half-year revenue of ¥272.82 billion for the period ended September 30, 2026, up from ¥232.53 billion in 2025. Net profit fell to ¥17.93 billion from ¥19.02 billion, and per-share earnings dropped to ¥29.47 from ¥30.50.American Banking and Market NewsAnalyzing Neuronetics (NASDAQ:STIM) & Sysmex (OTCMKTS:SSMXY)Sysmex and Neuronetics are compared on valuation, earnings, and analyst ratings. Sysmex has higher revenue and earnings, but Neuronetics trades at a lower P/E and has a stronger consensus rating with a $5.00 target price implying 132.56% upside.Defense WorldSysmex (OTCMKTS:SSMXY) vs. Hyperfine (NASDAQ:HYPR) Critical AnalysisA comparison of Hyperfine and Sysmex evaluates profitability, valuation, and analyst ratings. Hyperfine beats Sysmex on 8 of 15 factors, with a consensus target price of $2.02 implying 195.45% upside. Hyperfine is more volatile (beta 1.49) than Sysmex (beta 1.2).American Banking and Market NewsBoston Scientific (NYSE:BSX) and Sysmex (OTCMKTS:SSMXY) Financial ReviewBoston Scientific and Sysmex are compared on profitability, analyst ratings, and valuation. Boston Scientific has higher revenue, earnings, and a lower P/E ratio, with a consensus target price of $68.43 implying 57.94% upside. It beats Sysmex on 13 of 15 factors.YahooSysmex (TSE:6869) Stock May Be A Bargain On Cash FlowSysmex's share price has fallen 57.8% over five years, and its current ¥1,855 level is evaluated against cash flow. The DCF model estimates intrinsic value modestly above the current price, implying the market is not fully reflecting projected cash generation.Markets DailyFinancial Contrast: Sysmex (OTCMKTS:SSMXY) and Boston Scientific (NYSE:BSX)Boston Scientific and Sysmex are compared on profitability, analyst ratings, and valuation. Boston Scientific beats Sysmex on 12 of 14 factors, with higher revenue, lower P/E, and a consensus price target of $66.31 implying 55.25% upside.American Banking and Market NewsReviewing Sysmex (OTCMKTS:SSMXY) and Omnicell (NASDAQ:OMCL)Sysmex and Omnicell are compared on profitability, dividends, institutional ownership, risk, valuation, earnings, and analyst recommendations. Omnicell has a stronger consensus rating and a 63.16% upside target, while Sysmex shows higher revenue and a lower P/E ratio.